lyophilisation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-05. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
== Reporting of yields == In their 2010 Synlett article, Martina Wernerova and organic chemist, Tomáš Hudlický, raised concerns about inaccurate reporting of yields, and offered solutions—including the proper characterization of compounds. After performing careful control experiments, Wernerova and Hudlický said that each physical manipulation (including extraction/washing, drying over desiccant, filtration, and column chromatography) results in a loss of yield of about 2%. Thus, isolated yields measured after standard aqueous workup and chromatographic purification should seldom exceed 94%. They called this phenomenon "yield inflation" and said that yield inflation had gradually crept upward in recent decades in chemistry literature. They attributed yield inflation to careless measurement of yield on reactions conducted on small scale, wishful thinking and a desire to report higher numbers for publication purposes.
=== Extracellular matrix === Extracellular matrix materials are commercially available and are used in reconstructive surgery, treatment of chronic wounds, and some orthopedic surgeries; as of January 2017 clinical studies were under way to use them in heart surgery to try to repair damaged heart tissue. The use of fish skin with its natural constituent of omega 3, has been developed by an Icelandic company Kereceis. Omega 3 is a natural anti-inflammatory, and the fish skin material acts as a scaffold for cell regeneration. In 2016 their product Omega3 Wound was approved by the FDA for the treatment of chronic wounds and burns. In 2021 the FDA gave approval for Omega3 Surgibind to be used in surgical applications including plastic surgery.
For example, Nature published a total of 1,782 articles in the 2015/2016 biennium (902 articles in 2015 and 880 in 2016); and 74,090 references listed by articles published (by any journal) in 2017 were sourced from within the group of 1,782 articles that Nature had published during the previous two years. These figures yielded an impact factor of
Peristalsis is the rhythmic contraction of muscles that begins in the esophagus and continues along the wall of the stomach and the rest of the gastrointestinal tract. This initially results in the production of chyme which when fully broken down in the small intestine is absorbed as chyle into the lymphatic system. Most of the digestion of food takes place in the small intestine. Water and some minerals are reabsorbed back into the blood in the large intestine. The waste products of digestion (feces) are excreted from the rectum via the anus.
Sources: en.wikipedia.org
where : x, y, and z are the stoichiometric coefficients of each species. M stands for metal / metal ion, the L for Lewis bases, and finally Z for complex ions. Formation constants vary widely. Large values indicate that the metal has high affinity for the ligand, provided the system is at equilibrium. Sometimes the stability constant will be in a different form known as the constant of destability. This constant is expressed as the inverse of the constant of formation and is denoted as Kd = 1/Kf . This constant represents the reverse reaction for the decomposition of a complex ion into its individual metal and ligand components. When comparing the values for Kd, the larger the value, the more unstable the complex ion is. As a result of these complex ions forming in solutions they also can play a key role in solubility of other compounds. When a complex ion is formed it can alter the concentrations of its components in the solution. For example:
An enzyme inhibitor is characterised by its dissociation constant Ki, the concentration at which the inhibitor half occupies the enzyme. In non-competitive inhibition the inhibitor can also bind to the enzyme-substrate complex, and the presence of bound substrate can change the affinity of the inhibitor for the enzyme, resulting in a second dissociation constant Ki'. Hence Ki and Ki' are the dissociation constants of the inhibitor for the enzyme and to the enzyme-substrate complex, respectively. The enzyme-inhibitor constant Ki can be measured directly by various methods; one especially accurate method is isothermal titration calorimetry, in which the inhibitor is titrated into a solution of enzyme and the heat released or absorbed is measured. However, the other dissociation constant Ki' is difficult to measure directly, since the enzyme-substrate complex is short-lived and undergoing a chemical reaction to form the product. Hence, Ki' is usually measured indirectly, by observing the enzyme activity under various substrate and inhibitor concentrations, and fitting the data via nonlinear regression to a modified Michaelis–Menten equation.
=== Head and neck cancer === Tobacco smoking is the main risk factor for head and neck cancer. Cigarette smokers have a lifetime increased risk for head and neck cancer that is 5 to 25 times higher than the general population. The person who used to smoke's risk of developing head and neck cancer begins to approach the risk in the general population 15 years after smoking cessation. In addition, people who smoke have a worse prognosis than those who have never smoked. Furthermore, people who continue to smoke after a diagnosis of head and neck cancer have the highest probability of dying compared to those who have never smoked. This effect is seen in patients with HPV-positive head and neck cancer as well. Passive smoking, both at work and at home, also increases the risk of head and neck cancer. Using tobacco together with alcohol is an especially strong risk factor for head and neck cancer, causing 72% of all cases. This rises to 89% when looking specifically at laryngeal cancer. Smokeless tobacco (including products where tobacco is chewed) is also a cause of oral cancer. Cigar and pipe smoking are also important risk factors for oral cancer and have a dose-dependent relationship, with more consumption leading to higher chances of developing cancer. The use of electronic cigarettes may also lead to the development of head and neck cancers due to the substances like propylene glycol, glycerol, nitrosamines, and metals contained therein, which can cause damage to the airways.
==== Leucine ==== The ammonia fixed as part of the glutamate dehydrogenase enzyme reaction in the neurons is transaminated into α-ketoisocaproate to form the branched-chain amino acid leucine, which is exported to the astrocytes, where the process is reversed. α-ketoisocaproate is transported in the other direction.
In 1844, the Welsh scientist William Robert Grove postulated a relationship between mechanics, heat, light, electricity, and magnetism by treating them all as manifestations of a single "force" (energy in modern terms). In 1846, Grove published his theories in his book The Correlation of Physical Forces. In 1847, drawing on the earlier work of Joule, Sadi Carnot, and Émile Clapeyron, Hermann von Helmholtz arrived at conclusions similar to Grove's and published his theories in his book Über die Erhaltung der Kraft (On the Conservation of Force, 1847). The general modern acceptance of the principle stems from this publication. In 1850, the Scottish mathematician William Rankine first used the phrase the law of the conservation of energy for the principle. In 1877, Peter Guthrie Tait claimed that the principle originated with Sir Isaac Newton, based on a creative reading of propositions 40 and 41 of the Philosophiae Naturalis Principia Mathematica. This is now regarded as an example of Whig history.
Sources: en.wikipedia.org
=== Monoclonal anti-asprosin antibody === Mishra and colleagues have demonstrated that anti-asprosin mAbs (monoclonal antibody) are a dual-effect therapy that targets the two key pillars of metabolic syndrome – overnutrition and plasma glucose burden. Specifically, anti-asprosin mAbs have been shown to reduce blood glucose, appetite, and body weight in various diet-induced and genetic models of metabolic syndrome. These findings have led to an effort to optimize and develop clinical-grade anti-asprosin mAbs for use in humans. Asprosin has also been reported to cross the blood–brain barrier to regulate neurons in the hypothalamus of the brain known to regulate hunger and satiety, and inhibiting asprosin in obese mice reduced feeding and led to decreased body weight.
Illicit drug use in Mexico is low compared to the United States, but it is on the rise, with the availability of narcotics gradually increasing since the 1980s. The export rate of cocaine to the US decreased following stricter border control measures in response to the September 11 attacks. Drug shipments are often delayed in Mexican border towns before delivery to the U.S., which has forced drug traffickers to increase prices to account for transportation costs. These delays have contributed to the increased rates of local drug consumption. As a result of "spillover" along the U.S.-bound drug trafficking routes and more stringent border enforcement, Mexico's northern border states have seen increased levels of drug consumption and abuse, including elevated rates of drug injection, up to 10 to 15 times the national average. These rates are accompanied by mounting rates of HIV and STIs among injection drug users (IDUs) and sex workers, reaching a 5.5% prevalence in cities such as Tijuana and Ciudad Juárez, which also report STI rates of 64% and 83%, respectively. Violence and extortion of IDUs and sex workers directly and indirectly elevate the levels of risk behavior and poor health outcomes among members of these groups. Marginalization of these vulnerable groups by way of physical and sexual violence and extortion by police threatens the cross-over of infection from high-prevalence groups to the general population.
==== Mass spectrometry ==== Use of mass spectrometry as a second component of an operando experiment allows for optical spectra to be obtained before obtaining a mass spectrum of the analytes. Electrospray ionization allows a wider range of substances to be analysed than other ionization methods, due to its ability to ionize samples without thermal degradation. In 2017, Prof. Frank Crespilho and coworks introduced a new approach to operando DEMS, aiming the enzyme activity evaluation by differential electrochemical mass spectrometry (DEMS). NAD-dependent alcohol dehydrogenase (ADH) enzymes for ethanol oxidation were investigated by DEMS. The broad mass spectra obtained under bioelectrochemical control and with unprecedented accuracy were used to provide new insight into the enzyme kinetics and mechanisms.
The water activity, aw, in a fish is defined as the ratio of the water vapour pressure in the flesh of the fish to the vapour pressure of pure water at the same temperature and pressure. It ranges between 0 and 1, and is a parameter that measures how available the water is in the flesh of the fish. Available water is necessary for the microbial and enzymatic reactions involved in spoilage. There are a number of techniques that have been or are used to tie up the available water or remove it by reducing the aw. Traditionally, techniques such as drying, salting and smoking have been used, and have been used for thousands of years. These techniques can be very simple, for example, by using solar drying. In more recent times, freeze-drying, water binding humectants, and fully automated equipment with temperature and humidity control have been added. Often a combination of these techniques is used.
=== July === July 1, 2008: Denmark Denmark becomes the first European economy to confirm it is in recession since the global credit crunch began. Its GDP shrinks 0.6% in the first quarter after a 0.2% contraction in the fourth quarter of 2007.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.